Susan Moench, PhD, PA-C .
Results from an interim analysis of data from an ongoing, multiple basket trial showed clinical activity and generally good tolerability for the combination of pertuzumab plus trastuzumab in the cohort of patients with HER2-amplified metastatic colorectal cancer. ...